Harmony Biosciences Must Prove WAKIX Momentum Can Carry Street To Top Of Guidance

Harmony Biosciences enters its third-quarter report with a quiet but meaningful mismatch. Management kept its full-year WAKIX outlook unchanged after a record second quarter, yet Wall Street has drifted to the very top of that range. That leaves the November 4 report less about whether the narcolepsy franchise is healthy, which it clearly is, and more about whether it is growing fast enough to justify the most optimistic reading of the company's own forecast.

Analysts expect earnings of $1.03 per share on revenue of $273.7 million, up roughly 18% and 14% from a year ago, respectively. That is solid growth, though a step down from the 30% revenue jump posted last quarter. The guidance math is where things get interesting. Harmony booked about $477 million in WAKIX sales in the first half, so hitting the $1.04 billion high end requires roughly $563 million over the back half. The consensus full-year estimate sits right at $1.04 billion, and the third-quarter forecast implies a fourth quarter near $290 million. In other words, the Street is not just inside the range; it is leaning on the ceiling. A quarter that merely matches the midpoint pace of about $272 million would technically be fine but could invite a reset of year-end expectations.

The operating evidence that matters most is patient growth. Last quarter, Harmony added about 450 average patients, its best second-quarter gain ever, extending a streak of 400-plus additions in four of five quarters. Management also said its roughly 20% field force expansion is now fully hired, trained and deployed. This is the first full quarter where that larger sales team should be visibly productive, so another 400-plus increase would validate the investment, while a slowdown toward 300 would suggest the record quarter partly reflected a rebound from a seasonally weak first quarter rather than true acceleration.

The earnings line carries its own wrinkle. Cost of goods jumped to about 24% of revenue last quarter from 19% a year earlier, driven by royalties tied to a new license agreement. Management framed this as a lasting cost, not a one-off, which helps explain why consensus EPS sits well below the prior quarter's $1.28 even as revenue is expected to rise. If margins stabilize near that level, the model holds. Further creep would erode the operating leverage bulls are counting on, especially with an interim finance chief still in place.

Beyond the numbers, the pipeline has become central to the story. Early BP205 data showing a roughly 25-hour half-life and clean single-dose safety reframed the orexin program as Harmony's most important long-term asset, with multiple-dose results due in the fourth quarter. Any timing slippage would matter. Investors will also want an update on patent litigation with the last remaining generic filer, where closing arguments were scheduled for late October, since protecting exclusivity into 2030 underpins the entire valuation.

Sentiment has improved, with bearishness easing from about 29% to 19%, but it remains net negative. The stock has slightly lagged the S&P 500 since the last report, and at $36.83 it trades above its 200-day average yet well off the $43.49 post-earnings peak, closer to the bottom of its recent range. That tells a story of an initial rally that faded. The central question is whether WAKIX demand, amplified by the expanded sales force, is strong enough to keep the top of guidance in reach. If patient adds stay robust and margins hold, the case for a higher trajectory strengthens. If not, the Street's high-end positioning becomes the vulnerability.

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.